Reply to "Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in HBV patients"

Clin Mol Hepatol. 2024 Apr 11. doi: 10.3350/cmh.2024.0228. Online ahead of print.NO ABSTRACTPMID:38600870 | DOI:10.3350/cmh.2024.0228

Source: Clinical and molecular hepatology - April 11, 2024 Category: Gastroenterology Authors: Pin-Nan Cheng Ming-Lung Yu Source Type: research